EGFR tyrosine kinase inhibitors (TKIs) have prominently extended the overall survival and progression-free survival rates compared with conventional chemoradiotherapy for patients with advanced EGFR-mutant NSCLC [4, 7–9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.